These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 16921482)

  • 1. Overexpression of TGF-beta1 in esophageal (Barrett's) adenocarcinoma is associated with advanced stage of disease and poor prognosis.
    von Rahden BH; Stein HJ; Feith M; Pühringer F; Theisen J; Siewert JR; Sarbia M
    Mol Carcinog; 2006 Oct; 45(10):786-94. PubMed ID: 16921482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis.
    Yacoub L; Goldman H; Odze RD
    Mod Pathol; 1997 Feb; 10(2):105-12. PubMed ID: 9127315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
    Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR
    Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta 1 integrin expression in adenocarcinoma of Barrett's esophagus.
    Bottger TC; Youssef V; Dutkowski P; Seifert J; Maschek H; Brenner W; Junginger T
    Hepatogastroenterology; 1999; 46(26):938-43. PubMed ID: 10370643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.
    Wang KL; Wu TT; Choi IS; Wang H; Resetkova E; Correa AM; Hofstetter WL; Swisher SG; Ajani JA; Rashid A; Albarracin CT
    Cancer; 2007 Feb; 109(4):658-67. PubMed ID: 17211865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dedifferentiation precedes invasion in the progression from Barrett's metaplasia to esophageal adenocarcinoma.
    Helm J; Enkemann SA; Coppola D; Barthel JS; Kelley ST; Yeatman TJ
    Clin Cancer Res; 2005 Apr; 11(7):2478-85. PubMed ID: 15814623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 and ras gene expression in human esophageal cancer and Barrett's epithelium: a prospective study.
    Sorsdahl K; Casson AG; Troster M; Van Meyel D; Inculet R; Chambers AF
    Cancer Detect Prev; 1994; 18(3):179-85. PubMed ID: 8076380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathologic prognostic factors in Barrett's associated adenocarcinoma: a follow-up study of 96 patients.
    Torres C; Turner JR; Wang HH; Richards W; Sugarbaker D; Shahsafaei A; Odze RD
    Cancer; 1999 Feb; 85(3):520-8. PubMed ID: 10091725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multigene expression panel for the molecular diagnosis of Barrett's esophagus and Barrett's adenocarcinoma of the esophagus.
    Brabender J; Marjoram P; Salonga D; Metzger R; Schneider PM; Park JM; Schneider S; Hölscher AH; Yin J; Meltzer SJ; Danenberg KD; Danenberg PV; Lord RV
    Oncogene; 2004 Jun; 23(27):4780-8. PubMed ID: 15107828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
    Bacman D; Merkel S; Croner R; Papadopoulos T; Brueckl W; Dimmler A
    BMC Cancer; 2007 Aug; 7():156. PubMed ID: 17692120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation.
    Kimchi ET; Posner MC; Park JO; Darga TE; Kocherginsky M; Karrison T; Hart J; Smith KD; Mezhir JJ; Weichselbaum RR; Khodarev NN
    Cancer Res; 2005 Apr; 65(8):3146-54. PubMed ID: 15833844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma.
    Zou H; Osborn NK; Harrington JJ; Klatt KK; Molina JR; Burgart LJ; Ahlquist DA
    Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):830-4. PubMed ID: 15824152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Relations of transforming growth factor-beta1 expression to differentiation and prognosis of advanced gastric cancer].
    Guo RF; Zang SZ; Zhang L; Li WM; Hu FL; Lü YY
    Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(46):3249-54. PubMed ID: 17313802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Smad4 and transforming growth factor beta1 expression in patients with squamous cell carcinoma of the esophagus.
    Natsugoe S; Xiangming C; Matsumoto M; Okumura H; Nakashima S; Sakita H; Ishigami S; Baba M; Takao S; Aikou T
    Clin Cancer Res; 2002 Jun; 8(6):1838-42. PubMed ID: 12060625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia.
    Miller CT; Moy JR; Lin L; Schipper M; Normolle D; Brenner DE; Iannettoni MD; Orringer MB; Beer DG
    Clin Cancer Res; 2003 Oct; 9(13):4819-25. PubMed ID: 14581353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decrease in Le(x) expression in esophageal adenocarcinomas arising in Barrett's epithelium.
    Engel U; McCombs R; Stranahan P; Pettijohn D; Hage E
    Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):245-8. PubMed ID: 9107429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased c-myb mRNA expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.
    Brabender J; Lord RV; Danenberg KD; Metzger R; Schneider PM; Park JM; Salonga D; Groshen S; Tsao-Wei DD; DeMeester TR; Hölscher AH; Danenberg PV
    J Surg Res; 2001 Aug; 99(2):301-6. PubMed ID: 11469901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors, DNA damage, and disease progression in Barrett's esophagus.
    Olliver JR; Hardie LJ; Gong Y; Dexter S; Chalmers D; Harris KM; Wild CP
    Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):620-5. PubMed ID: 15767340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma.
    Brabender J; Marjoram P; Lord RV; Metzger R; Salonga D; Vallböhmer D; Schäfer H; Danenberg KD; Danenberg PV; Selaru FM; Baldus SE; Hölscher AH; Meltzer SJ; Schneider PM
    Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2113-7. PubMed ID: 16172218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prediction of response to neoadjuvant chemotherapy in Barrett's carcinoma by quantitative gene expression analysis].
    Langer R; Specht K; Becker K; Ewald P; Sarbia M; Busch R; Feith M; Stein HJ; Siewert JR; Höfler H
    Verh Dtsch Ges Pathol; 2004; 88():207-13. PubMed ID: 16892554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.